NYSE:LLYPharmaceuticals
Eli Lilly Expands Beyond GLP-1s With Autoimmune, Gene-Editing And US Build-Out
Eli Lilly (NYSE:LLY) has entered a collaboration with Repertoire Immune Medicines to develop tolerizing therapies for autoimmune diseases.
The company has also partnered with Seamless Therapeutics on programmable gene editing treatments for certain forms of hearing loss.
Eli Lilly plans to invest over $3.5b in a new Pennsylvania manufacturing facility focused on next generation injectable medicines.
Eli Lilly is already widely associated with obesity treatments, and these moves show the...